Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A | Q12879 | 12/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 11/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636699 | 1.00 | GRIN2A (1.00) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16636514 | 1.00 | GRIN2A (1.00) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL17971451 | 0.91 | GRIN2A (0.84) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16645771 | 0.91 | GRIN2A (0.84) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16636545 | 0.91 | GRIN2A (0.83) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16645767 | 0.91 | GRIN2A (0.83) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16645435 | 0.91 | GRIN2A (0.83) | GRIN2AGRIN1GRIA2MAPTRXFP1 | |
| SCHEMBL16636539 | 0.91 | GRIN2A (0.83) | GRIN2AGRIN1GRIA2MAPTRXFP1 | |
| SCHEMBL16645436 | 0.90 | GRIN2A (0.82) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16636489 | 0.90 | GRIN2A (0.82) | GRIN2AGRIN1GRIA2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | claimed |
| EP-3055315-B1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2018-07-25 | — | — | EP | claimed |
| US-9988400-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2018-06-05 | — | — | US | claimed |
| US-20260071276-A1 | GPCR LATROPHILIN-3 AS BIOMARKER FOR DETECTING INCREASED RISK FOR MILD BRAIN INJURY AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF THE SAME | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | ALTO NEUROSCIENCE INC (US) | 2026-03-05 | — | — | US | disclosed |
| CN-115160269-A | Arylcarboxamide derivatives as positive allosteric modulators of NMDAR | 北京大学 | 2022-10-11 | — | — | CN | disclosed |
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3415519-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2018-12-19 | — | — | EP | disclosed |
| US-20180244694-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3055315-B1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-9988400-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-3055315-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-20160222033-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015052226-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | TPMT, THPO, CYP11B2 | GRIN2A 2506/4885GRIN1 2250/4885GRIA2 2761/4885 |
| US-20260071276-A1 | GPCR LATROPHILIN-3 AS BIOMARKER FOR DETECTING INCREASED RISK FOR MILD BRAIN INJURY AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF THE SAME | GPR3, OPRL1, ADGRF1 | GRIN2A 502/4885GRIN1 567/4885GRIA2 377/4885 |
| US-20180244694-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | TPMT, THPO, CYP11B2 | GRIN2A 2506/4885GRIN1 2250/4885GRIA2 2761/4885 |
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | NTRK2, BDNF, GRIN2A | GRIN2A 3/4885GRIN1 14/4885GRIA2 31/4885 |
| US-20160222033-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | TPMT, THPO, CYP11B2 | GRIN2A 2506/4885GRIN1 2250/4885GRIA2 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.